The discovery and development of GLP-1 receptor agonists for type 2 diabetes and obesity is a bench-to-bedside success story.1 Multiple GLP-1 receptor agonists are now in clinical use, such as ...

Treatment with exenatide, a GLP-1 receptor agonist, was comparable to placebo in slowing the rate of Parkinson’s disease ...

This wireless DBS nanosystem primarily has three advantages: It leverages the endogenously expressed TRPV1 receptors in dopaminergic neurons of the substantia nigra, eliminating the need for ...

Destruction of the ascending dopaminergic pathway, blocking of dopamine receptors by drugs, inhibition of dopamine synthesis, or prevention of dopamine storage has been shown to induce akinesia on ...

low doses of caffeine prevent the process of activation of the mesolimbic dopaminergic pathway by alcohol through a mechanism of action that involves specific receptors and alcohol’s metabolism ...

This wireless DBS nanosystem has three primary advantages: It leverages the endogenously expressed TRPV1 receptors in dopaminergic neurons of the substantia nigra, eliminating the need for ...